Eszopiclone Reference

Plain English

What it is

Eszopiclone (brand name Lunesta) is a prescription sleep medicine called a z-drug, a type of sedative-hypnotic. The FDA approved it to treat insomnia, which means ongoing trouble falling or staying asleep. It is a Schedule IV controlled substance, so it is regulated for its potential to be habit-forming.

What people use it for

People take it to fall asleep faster and stay asleep through the night. In the insomnia community it is well known for a long study that followed people using it nightly over half a year.

What the science shows

A large, carefully run human trial found it kept helping adults with long-term insomnia across six months of nightly use, which is one of the longer studies for any sleep drug. This is real human evidence, not just lab or animal work.

The catch

This medicine carries the FDA's strongest warning, called a boxed warning, about complex sleep behaviors. People have walked, driven, or done other things while not fully awake and with no memory of it, and some of these events have caused serious injury or even death. It can also leave people drowsy the next morning in ways that affect driving, and the chance of dependence goes up the longer it is used.

Reference summary

Krystal 2003 Sleep demonstrated sustained efficacy over 6 months of nightly treatment in adults with chronic insomnia - one of the longer-duration sustained-efficacy datasets for any hypnotic. The 2014 FDA dose-reduction recommendation lowered the starting dose from 2 mg to 1 mg based on next-morning driving impairment data.

Regulatory and posture

Categories

Sleep

Aliases

Lunesta, S-enantiomer of zopiclone, Non-benzodiazepine GABA-A agonist (small molecule, not a peptide)

Evidence posture

human - 2014 FDA dose reduction (2 mg -> 1 mg starting dose) due to next-morning driving impairment. Same class-level safety concerns as zolpidem.

Regulatory status

FDA-approved as Lunesta (2004) for the treatment of insomnia. Schedule IV controlled substance. The recommended starting dose was reduced in 2014 (FDA safety announcement on next-morning impairment).

Content review status

label verified